Literature DB >> 36001859

Bayesian Sample Size Planning Tool for Phase I Dose-Finding Trials.

Xiaolei Lin1, Jiaying Lyu2, Shijie Yuan2, Dehua Bi2, Sue-Jane Wang3, Yuan Ji4.   

Abstract

PURPOSE: Through Bayesian inference, we propose a method called BayeSize as a reference tool for investigators to assess the sample size and its associated scientific property for phase I clinical trials.
METHODS: BayeSize applies the concept of effect size in dose finding, assuming that the maximum tolerated dose can be identified on the basis of an interval surrounding its true value because of statistical uncertainty. Leveraging a decision framework that involves composite hypotheses, BayeSize uses two types of priors, the fitting prior (for model fitting) and sampling prior (for data generation), to conduct sample size calculation under the constraints of statistical power and type I error.
RESULTS: Simulation results showed that BayeSize can provide reliable sample size estimation under the constraints of type I/II error rates.
CONCLUSION: BayeSize could facilitate phase I trial planning by providing appropriate sample size estimation. Look-up tables and R Shiny app are provided for practical applications.

Entities:  

Mesh:

Year:  2022        PMID: 36001859      PMCID: PMC9489190          DOI: 10.1200/PO.22.00046

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  22 in total

1.  Escalation, group and A + B designs for dose-finding trials.

Authors:  Anastasia Ivanova
Journal:  Stat Med       Date:  2006-11-15       Impact factor: 2.373

2.  The i3+3 design for phase I clinical trials.

Authors:  Meizi Liu; Sue-Jane Wang; Yuan Ji
Journal:  J Biopharm Stat       Date:  2019-07-15       Impact factor: 1.051

3.  A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.

Authors:  Wentian Guo; Sue-Jane Wang; Shengjie Yang; Henry Lynn; Yuan Ji
Journal:  Contemp Clin Trials       Date:  2017-04-27       Impact factor: 2.226

4.  Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.

Authors:  Yuan Ji; Sue-Jane Wang
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

5.  A modified toxicity probability interval method for dose-finding trials.

Authors:  Yuan Ji; Ping Liu; Yisheng Li; B Nebiyou Bekele
Journal:  Clin Trials       Date:  2010-10-08       Impact factor: 2.486

6.  Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.

Authors:  Fangrong Yan; Sumithra J Mandrekar; Ying Yuan
Journal:  Clin Cancer Res       Date:  2017-05-25       Impact factor: 12.531

7.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

8.  Sample size formulae for the Bayesian continual reassessment method.

Authors:  Ying Kuen Cheung
Journal:  Clin Trials       Date:  2013-08-21       Impact factor: 2.486

9.  Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.

Authors:  Ying Yuan; Ruitao Lin; Daniel Li; Lei Nie; Katherine E Warren
Journal:  Clin Cancer Res       Date:  2018-05-16       Impact factor: 12.531

10.  A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.

Authors:  Yanhong Zhou; J Jack Lee; Ying Yuan
Journal:  Stat Med       Date:  2019-10-17       Impact factor: 2.373

View more
  1 in total

1.  Bayesian Sample Size Planning Tool for Phase I Dose-Finding Trials.

Authors:  Xiaolei Lin; Jiaying Lyu; Shijie Yuan; Dehua Bi; Sue-Jane Wang; Yuan Ji
Journal:  JCO Precis Oncol       Date:  2022-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.